Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

The effects of green cardamom on blood glucose indices, lipids, inflammatory factors, paraxonase-1, sirtuin-1, and irisin in patients with nonalcoholic fatty liver disease and obesity: study protocol for a randomized controlled trial

  • Milad Daneshi-Maskooni1,
  • Seyed Ali Keshavarz2Email author,
  • Siavash Mansouri3,
  • Mostafa Qorbani4,
  • Seyed Moayed Alavian5,
  • Mahtab Badri-Fariman1,
  • Seyed Ali Jazayeri-Tehrani2 and
  • Gity Sotoudeh1Email author
Trials201718:260

https://doi.org/10.1186/s13063-017-1979-3

Received: 28 November 2016

Accepted: 8 May 2017

Published: 7 June 2017

Abstract

Background

The relationship between dietary components and nonalcoholic fatty liver disease (NAFLD) needs to be further investigated. The potential health benefits of cardamom have been found in some studies. Cardamom showed beneficial effect on hepatomegaly, dyslipidemia, and fasting hyperglycemia in animals. However, some adverse effects of cardamom have been reported in animals. No previous human study had been conducted on the effects of cardamom in NAFLD. This study aims to determine the effects of green cardamom (Elettaria cardamomum) supplementation on blood glucose indices, lipids, inflammatory profiles, and liver function, especially by examining irisin, paraxonase-1 (PON1) and sirtuin-1 (Sirt1) in obese patients with NAFLD.

Methods

This trial is to be conducted at the polyclinic of the National Iranian Oil Company (NIOC) Central Hospital, Tehran. Eighty obese patients with NAFLD will be selected according to the eligibility criteria. The NAFLD diagnosis method is ultrasonography. Patients will be randomly divided into two groups by a random-number table (cardamom and placebo groups, two 500-mg capsules, three times/day, taken with meals for 3 months, follow-up monthly). General characteristics, dietary intakes (at the beginning, middle, and end), and physical activity (at the beginning and end) will be assessed using a general, 24-h food recall, and short-form International Physical Activity Questionnaires (IPAQ), respectively. Lifestyle advice will be presented to both groups identically. At the beginning and the end, anthropometrics (weight, height, and waist circumference), blood pressure, extent of fatty liver, and blood biomarkers, including serum glucose indices (fasting blood sugar (FBS)) and insulin (FBI), homeostasis model assessment-insulin resistance (HOMA-IR), Quantitative Insulin Sensitivity Check Index (QUICKI)), lipids (triglyceride (TG), low-density lipoprotein-cholesterol (LDL-c), high-density lipoprotein-cholesterol (HDL-c), total cholesterol (TC)), inflammatory markers (highly sensitive C-reactive protein (hs-CRP), tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6)), liver enzymes (alanine transaminase (ALT), aspartate transaminase (AST)), irisin, PON1, and Sirt1, will be determined.

Discussion

This trial would be the first to assess the effects of green cardamom on several blood factors, including glucose indices, lipids, inflammatory markers, liver enzymes, irisin, PON1, and Sirt1, and blood pressure and anthropometry in obese patients with NAFLD. Further study of cardamom’s potential in improving NAFLD is suggested.

Trial registration

Iranian Registry of Clinical Trials (IRCT), ID number: IRCT2015121317254N4. Registered on 27 December 2015.

Keywords

TrialProtocolNonalcoholic fatty liver diseaseGreen cardamomOverweightObesity

Background

NAFLD is engendered due to the accumulation of large amounts of triglycerides in liver cells (5% <) [1]. The prevalence of NAFLD is currently increasing [2] (an average of 30% in Iranian adults [3, 4]). NAFLD prevalence in obese (Body Mass Index (BMI) ≥25) and nonobese (BMI <25) adults has been reported as being approximately 65–85% and 15–20%, respectively [5]. The pathology of NAFLD is a two-stage phenomenon, including the accumulation of fat in hepatocytes and subsequent hepatic steatosis in the first stage, and nonalcoholic steatohepatitis (NASH) in the second stage. Insulin resistance plays a key role in both stages and oxidative stress and proinflammatory cytokines are major stimulating components of the pathology [6]. NAFLD, being a major health problem, includes a wide range of clinical symptoms (from the asymptomatic fatty liver to severe inflammation along with fibrosis and sometimes cirrhosis). Often, these patients are insulin-resistant [7]. Insulin resistance is directly correlated with the content of fat in the liver. Nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-κB) is a protein complex responsible for cytokine production and cell survival. Known triggers of NF-κB include reactive oxygen species (ROS), tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), bacterial lipopolysaccharide, isoproterenol, cocaine, and ionizing radiation. NF-κB activation upregulates the production of proinflammatory cytokines that affect both local and systemic insulin action. This means that inflammation, adipokines, oxidative stress, and lipid metabolites can affect insulin sensitivity, but are not necessarily directly associated with intrahepatic fat content [5]. Most patients with NAFLD have metabolic syndrome characteristics, including being overweight and obese, impaired glucose tolerance, hyperlipidemia and hypertension [8, 9]. Other risk factors of NAFLD are age, family history, malnutrition, severe weight loss, the consumption of certain medicines, certain diseases [10], and gastrointestinal microbiota [11].

Along with increasing oxidative stress, both the activity and production of bonded-to-high-density lipoprotein-cholesterol (HDL-c) blood PON1 is suppressed in patients with NAFLD [12, 13]. PON1 has an anti-inflammatory role by interfering with the production of inflammatory factors [12]. PON1 is activated by peroxisome proliferator-activated receptor gamma (PPAR-γ) [14] and, according to previous studies, the intake of dietary polyphenols (particularly flavons) is associated with increasing PPAR-γ [1517].

Irisin is a newly identified myokine related to exercise. Recently, it was reported that serum irisin levels have shown associations with intrahepatic triglyceride content which is indicative of it playing an important hepatic role [18]. According to recent studies, irisin plays a role in insulin sensitivity [1822] through effects on glucose and lipid metabolism [19, 23] and increased thermogenesis [19, 20, 24]. Its secretion can be increased by lifestyle modifications, regular exercise [2022, 24, 25], and stress [21]. In a human study, serum irisin levels were inversely associated with the triglyceride (TG) content in the liver and liver enzymes in obese adults (aged 40 years and older) with NAFLD [26].

Sirtuins have seven categories, of which Sirt1 has mainly been identified and studied in humans [27]. Sirt1, as a histone deacetylase class III, decreases oxidative stress indirectly through catalase and superoxide dismutase (SOD) [28]. Sirt1 activation has beneficial health consequences such as improved insulin sensitivity, obesity reduction, increased mitochondrial function, decreased glucose levels, and increased physiological functions [29, 30]. Sirt1 plays an important role by increasing PPAR-γ co-activator-1 alpha (PGC-1α) [27, 29]. Usually, polyphenols activate Sirt1 and, subsequently, PGC-1α also inhibits NF-κB [29, 31].

Dietary polyphenols including derivatives and isomers of flavones, isoflavones, flavonoids and catechins and phenolic acids have antioxidant and anti-inflammatory properties [32]. Green cardamom (Elettaria cardamomum) contains phenolic and flavonoid compounds, such as flavonols (quercetin and kaempferol), flavone (luteolin) and anthocyanidin (pelargonidin) [33], that are inhibitors of NF-κB [3336]. Isoflavones and flavonoids, such as quercetin, resveratrol [37], and kaempferol, increase the activity of PGC-1α [38]. On the other hand, irisin secretion increases in response to increasing PGC-1α [25]. Owing to the effect of dietary polyphenols on PGC-1α, it is possible that green cardamom polyphenols will be able to influence thermogenesis and improve insulin resistance. Moreover, in cell studies, irisin effectively prevents hepatic steatosis by lipogenic gene expression changes and oxidative stress inhibition [18]. In addition, irisin leads to fibroblast growth factor-21 (FGF-21) upregulation through the PPAR signaling pathway, especially PPAR-α [22], which can subsequently improve insulin sensitivity and hepatic steatosis [22, 26].

Lifestyle changes—including gradual weight loss and increasing physical activity—are common ways to reduce and treat NAFLD [3943]. Since achieving weight loss and maintaining a reduced weight for a long time is difficult [44], it seems that dietary changes may be a proposed therapeutic approach for these patients [45]. Some studies were conducted on green cardamom’s role in health as a spice. The effects of cardamom reported by those studies are blood pressure lowering, fibrinolysis enhancing, antispasmodic effects, and gastroprotective, antibacterial, antioxidant [46], anti-inflammatory, anti-food poisoning, carminative, diuretic, expectorant, heart-function improving, anticarcinogenic [47], and antiplatelet aggregation effects [48]. Cardamom volatile oil contains terpenes, esters, flavonoids and other compounds. The major constituents of the volatile oil of cardamom include about 36% 1,8-cineole, 31% alpha-terpinil acetate, 12% limonene, 3% sabinene and others. Most studies have been conducted on the 1,8-cineole compound. The reported effects are apoptotic, the inhibiting of cytokines, prostaglandins, leukotrienes, and nitric oxide (inhibition of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS)), TNF-α and IL-1β inhibition, liver necrosis reduction, cardiovascular effects (blood vessel relaxation), as well as anticholinergic effects and the blocking of muscarinic receptors [49].

The hypothesis is that the antioxidant, anti-inflammatory, antibacterial, and hypolipidemic activities of cardamom can improve NAFLD. The effects of cardamom on Sirt1 secretion and, subsequently, PGC-1α, irisin, and insulin sensitivity are not clear. Moreover, its effects on PPAR-γ and, subsequently, serum PON1 levels need further study. With an awareness that NAFLD increases in overweight or obese populations, and the lack of human studies on the effects of green cardamom, this clinical trial study was planned to determine its impact on blood glucose indices, lipids and inflammatory profiles, liver function, and insulin resistance, especially through irisin, PON1, and Sirt1.

Methods

Study design and objectives

A double-blind randomized clinical trial design is to be used in this study.

Objectives

  • × Compare the mean serum lipid (triglycerides (TG), total cholesterol (TC), low-density lipoprotein (LDL), high-density lipoprotein (HDL)) and glucose indices (fasting blood sugar (FBS), fasting blood insulin (FBI), homeostasis model assessment-insulin resistance (HOMA-IR), Quantitative Insulin Sensitivity Check Index (QUICKI)) between the two groups and within each group, before and after intervention

  • × Compare the mean serum inflammatory factors (TNF-α, interleukin-6 (IL-6), highly sensitive C-reactive protein (hs-CRP)) between the two groups and within each group, before and after intervention

  • × Compare the mean of serum PON1, sirt1, and irisin between the two groups and within each group, before and after intervention

Inclusion criteria

  • × NAFLD diagnosed by a radiologist and a hepatologist using ultrasonography, and divided into one of three categories (mild, moderate or severe degree)

  • × Age 30–60 years

  • × Overweight or obese (25 ≤ BMI < 35)

  • × Informed consent signed and dated by the subject and investigator

Exclusion criteria

  • × History of alcohol consumption during the preceding 12 months, based on patient’s own evidence

  • × Suffering from cognitive impairment or other psychotic illnesses, as diagnosed by a psychiatrist

  • × Severe depression, lacking the ability to cooperate and answer questions

  • × Diagnosed pathological conditions affecting the liver such as viral hepatitis, acute or chronic liver failure, cholestasis, liver transplantation, habitual abuse of nonsteroidal anti-inflammatory drugs, antibiotics, antisecretory drugs causing achlorhydria within 3 months before the study, corticosteroids, amiodarone, valproate, prednisone, tamoxifen, perhexiline and methotrexate, rapid weight loss, diabetes, heart failure, thyroid disorders, kidney disease, respiratory failure, psychological disorders, hereditary hemochromatosis and Wilson’s disease, alpha-1 antitrypsin deficiency, autoimmune diseases, celiac disease, use of liver fat inducers, and hormonal drugs

  • × Acute systemic disease, cystic fibrosis, muscular dystrophy, protein malnutrition, a history of gastrointestinal surgery, neurological disorders, structural abnormalities of the gastrointestinal tract

  • × NAFLD caused by secondary factors including drugs, surgical procedures, environmental toxins, and total parenteral nutrition (TPN)

  • × Conditions leading to physical inactivity (disability)

  • × Uncontrolled hypertension (>140/90 mmHg)

  • × Any diagnosed malignancy

  • × Breast feeding, pregnant, and/or planning for pregnancy in the following 3 months

  • × Professional athlete or doing regular exercise

  • × Treatment with statins, antihypertensive drugs, ursodeoxycholic acid, probiotics, and multivitamin-mineral and antioxidant supplements during the past 3 months

  • × Surgery for weight loss in the past year and weight loss in the past 3 months

  • × Intake of drugs that interact with cardamom including aspirin, anticoagulants (warfarin, heparin) and antiplatelet (clopidogrel), nonsteroidal anti-inflammatory (ibuprofen or naproxen), blood pressure-lowering drugs, central nervous system (CNS) depressants (benzodiazepines such as lorazepam or diazepam, barbiturates such as phenobarbitals, narcotics such as codeine, some antidepressants and alcohol), anaesthetics, antibiotics, anticancer agents, anticholinergics, antifungals, cyproheptadine, diuretics (loop), estrogen, indomethacin, muscarinic agents, pain relievers and prednisolone

  • × Taking a multivitamin-mineral or antioxidant supplement at least once a week during the study

  • × Not taking more than 10% of prescription supplements

Study subjects

Patients with NAFLD attending the polyclinic of the NIOC Central Hospital in Tehran are to be invited to the study. The patients will be diagnosed by a radiologist and a hepatologist as having fatty liver, using ultrasonography. Patients should meet the eligibility criteria. After their identification, the patients will be referred to the principal investigator.

First, the goals, methods, and benefits of the intervention will explained and Informed Consent Forms signed. The general questionnaire, short-form International Physical Activity Questionnaire (IPAQ) and 24-h food recall questionnaire are to be completed by interviews. Necessary education and guidelines concerning lifestyle modification, will then be given [45], including a weight-loss diet (5% weight loss during the study [50]) and increasing physical activity (aerobic with moderate intensity, at least 3 times per week, 30–45 min [51]).

Anthropometric measurements, including weight, height and waist circumference are to be assessed by using a digital scale, stadiometer, and nonelastic tape, respectively.

A 24-h food recall questionnaire is to be completed at the beginning, after 1.5 months, and at the end. Blood pressure (systolic and diastolic) will be measured at the beginning and the end with a manometer. Ten milliliters of blood at the beginning and 10 ml at the end are taken from a peripheral vein after a 12-h overnight fast. After centrifuging for 20 min (3000 g), the serum samples will be frozen simultaneously and stored at −80 °C until analyzed. At the end, the evaluated outcomes are to be presented to the patients privately.

The sample size

The sample size was calculated using the “two mean comparison formula” and was related to a previous study [52] which had assessed the effects of cardamom on lipid profiles. In this study, the errors I and II are considered to be 0.05 and 0.2, respectively. The mean difference of TG between the groups was 5 mg/dl, and the standard deviation of each group was 8 mg/dl. The sample size was determined to be 40 subjects in each group. In total, 80 patients were invited and randomly divided into two groups as follows:
  1. 1.

    Forty overweight or obese patients with NAFLD will be given lifestyle change recommendations (weight-loss diet (5%) during the study and increasing physical activity) and a green cardamom supplement for 3 months

     
  2. 2.

    Forty overweight or obese patients with NAFLD will be given lifestyle change recommendations (weight loss diet (5%) during the study and increasing physical activity) and a placebo supplement for 3 months

     

Randomization and intervention

Patients are divided into two equal groups using block randomization. Stratified randomization will be used to control age and gender distribution. In this study, the ratio of green cardamom and placebo supplementation groups is 1:1. The block randomization is performed by an assistant and the intervention allocation is blinded for both the investigator and subjects. The participants are randomly placed into two groups receiving whole green cardamom powder or toast powder supplements. Cardamom and placebo capsules are prepared by the Traditional Medicine Research Center (TMRC), Iran University of Medical Sciences. Each capsule contains 0.5 g of whole green cardamom or toast powder. Placebo and cardamom capsules are similar in shape, size, and color. At the beginning of the study, all placebo capsules are to be placed near the cardamom capsules so that the patients are able to smell them. Even though some cardamom volatile oils may be absorbed by the placebo capsules, this amount is considered negligible compared to the amounts that affect health indicators. The type of supplements is blinded as A and B packages for investigators and patients.

According to previous trials, the dose of whole green cardamom powder was determined to be 3 g per day [46, 52, 53]; two capsules were consumed with each meal.

The voucher number of green cardamom is Elettaria cardamomum (L.) Maton, Family: Zingiberaceae, PMP-669. An essential oil percentage and the total content of phenolic and flavonoid compounds of green cardamom will be assessed using high-performance liquid chromatography (HPLC) and gas chromatography mass spectrometry (GC-MS) in the institute of medicinal plants, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Some polyphenolic compounds of green cardamom, whose effects have been mentioned in other articles (caffeic acid, gallic acid, quercetin and luteolin), will also be determined by using HPLC.

Supplements are to be distributed among patients once a month and their potential complications and consumption processes registered (number of consumed capsules and the returned packages). In addition, the consumption process is to be checked once a week, by telephone.

Lifestyle changes

A weight-loss diet (5% weight loss during the study), recommendations for increasing physical activity (aerobic with moderate intensity, at least three times per week at 30–45 min), and lifestyle changes will be presented to all patients enrolled for the study by an experienced dietician placed in the polyclinic of the NIOC Central Hospital in Tehran.

Measurements and assessments

The grade of fatty liver is to be determined in a fasting state by medical ultrasound (also known as diagnostic sonography or ultrasonography). This is a diagnostic imaging technique which applies ultrasound in order to examine the images of internal bodily organs and structures such as the liver. Its aim is often to find the source of a disease or to exclude any pathology. One radiologist will do the ultrasound diagnostic imaging for all patients to reduce human error differences.

Serum lipid profile (TC, HDL, LDL, TG) and liver enzymes (alanine transaminase (ALT), aspartate transaminase (AST)) are to be measured by using the specific kits and Hitachi analyzer (or BT-3500) device. Serum lipid profile has now become almost a routine test. These will be done in a 12-h fasting state.

Blood glucose profiles, including FBS, FBI, HOMA-IR, and QUICKI are measured by a glucose specific kit (glucose oxidase method), electrochemiluminescence ((ECL) by the cobas e 411® analyzer device) and the following formulae, respectively:
$$ \mathrm{QUICKI}=1/\left( \log\ \left(\mathrm{fasting}\ \mathrm{insulin}\kern0.5em \mu \mathrm{U}/\mathrm{ml}\right)+ \log\ \left(\mathrm{fasting}\ \mathrm{glucose}\ \mathrm{mg}/\mathrm{dl}\right)\right) $$
$$ \mathrm{HOMA}\hbox{-} \mathrm{I}\mathrm{R}=\left(\mathrm{FBI}\ \left(\mathrm{mU}/\mathrm{l}\right)\times \mathrm{FBS}\ \left(\mathrm{mmol}/\mathrm{l}\right)\right)/22.5 $$

Glucose oxidase is widely used for the determination of free glucose level in body diagnostic fluids.

Serum inflammatory factors (IL-6, TNF-α, hs-CRP), irisin, Sirt1 and PON1 are measured by using the enzyme-linked immunosorbent assay (ELISA) method (sandwich ELISA format) and specific kits.

The ELISA is a test that uses antibodies and color change to identify a substance. The ELISA is often used as a diagnostic tool in medicine [54]. The ELISA test will be done by Elisa washer (Combiwash Human®) and bioElisa reader devices (biokit® ELx800) in this study.

Food intake and physical activity are to be assessed by using a 24-h food recall (at the beginning, after 1.5 months, and at the end) questionnaire and short-form IPAQ (at the beginning and the end), respectively.

The patients will be asked to remember all consumed food and drink during the past 24 h when completing the 24-h food recall questionnaire. This questionnaire has previously been validated in Iran [55]. The intake values will be turned to g/day, based on household food scales [56]. The dietary intakes are to be calculated by using the DFP (Dorosty Food Processor) software that contains Iranian food composition tables [55]. The intake of macronutrients and micronutrients including dietary antioxidants will thus be determined.

The purpose of the IPAQ is to provide a set of well-developed instruments that can be used internationally to obtain comparable estimates of physical activity. The short version of the questionnaire is suitable for use in national and regional surveillance systems and provides information required in research work or for evaluation purposes. Three levels (categories) of physical activity are proposed: low, moderate, and high [57]. This questionnaire has been validated in previous studies [5860] including in Iran [61, 62].

The effect of dietary intakes, including dietary antioxidants and physical activity, will be controlled by prescribing the same diet and physical activity for all patients in both groups.

Systolic and diastolic blood pressure values will be measured with a mercury manometer at the beginning and the end of the study. Values are to be recorded in millimeters of mercury (mmHg).

Weight, height and waist circumference are determined by using a digital scale, stadiometer and nonelastic tape, respectively. They are measured thus: weight without shoes, with minimal clothing, and with a 100-g accuracy; height without shoes, standing, heels against the wall, flat and forward head, and with 0.5-cm accuracy; and waist circumference with minimal clothing, midway between the last rib and the iliac crest.

Collection of blood, specimen storage, and laboratory tests are to be conducted at the NIOC Central Hospital in Tehran.

Figure 1 presents the overall contents of enrollment, interventions, and assessments. Moreover, the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Checklist is provided as an Additional file 1.
Fig. 1

Contents include enrollment, interventions, and assessments

The trial conduct is to be frequently audited by an assistant through an independent process.

Data analysis

Data entry, coding, security, and storage are also to be considered. The normality of continuous variables will be determined using a Kolmogorov-Smirnov test. Continuous and categorical baseline characteristics of the groups will be assessed using a t test and a chi-square test, respectively. Multivariate, two-factor, repeated measures analysis of variance will be used to assess time effects and to analyze time × treatment interaction effects on all dependent variables. All statistical measurements will be reported with 95% confidence interval (CI). A P value < 0.05 will be considered as statistically significant. The data will be analyzed by using SPSS software.

Data accessibility

The principal investigator will have access to the final trial dataset, and such access for other investigators is limited. The trial results are presented only through the publication.

Discussion

This trial will first assess the effects of green cardamom (Elettaria cardamomum) on blood glucose indices, lipids, inflammatory factors, paraxonase-1, sirtuin-1 and irisin in overweight or obese patients with nonalcoholic fatty liver disease (NAFLD). The different clinical usages and the lack of awareness concerning the advantages and disadvantages of green cardamom in patients with NAFLD makes this study very pertinent. Although there is a hypothetical reason for using green cardamom in the treatment of some disorders, its therapeutic use in humans necessitates the study of its potential in different diseases, particularly NAFLD. Attention should be paid to the increasing rates of obesity (and, consequently, NAFLD). Due to remarkable changes of some blood markers in this population, and the lack of human studies on the effects of green cardamom, this trial selected these patients as the most suitable cases for intervention.

The strengths of the study are its randomized double-blinded design, protocol publication, the measurement of dietary outcomes and physical activity status, and the recording of patient-reported probable complications.

The limitations of the study are self-reporting of diet and physical activity, slow patient recruitment because of the eligibility criteria, a single center and lack of cooperation by some patients at the end, which may lead to these patients needing to be being replaced.

Trial status

Recruitment of the participants was ongoing at the time of manuscript submission.

Abbreviations

ALT: 

Alanine transaminase

ANCOVA: 

Analysis of covariance

AST: 

Aspartate transaminase

BMI: 

Body Mass Index

CNS: 

Central nervous system

COX-2: 

Cyclooxygenase-2

DFP: 

Dorosty Food Processor

ECL: 

Electrochemiluminescence

ELISA: 

Enzyme-linked immunosorbent assay

FBI: 

Fasting blood insulin

FBS: 

Fasting blood sugar

FGF-21: 

Fibroblast growth factor-21

GC-MS: 

Gas chromatography mass spectrometry

HDL-c: 

High-density lipoprotein-cholesterol

HOMA-IR: 

Homeostasis model assessment-insulin resistance

HPLC: 

High-performance liquid chromatography

hs-CRP: 

High-sensitivity C-reactive protein

IL-1β: 

Interleukin-1 beta

IL-6: 

Interleukin-6

iNOS: 

Inducible nitric oxide synthase

IPAQ: 

International Physical Activity Questionnaire

LDL-c: 

Low-density lipoprotein-cholesterol

NAFLD: 

Nonalcoholic fatty liver disease

NASH: 

Nonalcoholic steatohepatitis

NF-κB: 

Nuclear factor kappa-light-chain-enhancer of activated B-cells

NIOC: 

National Iranian Oil Company

PGC-1α: 

PPAR-γ co-activator-1 alpha

PON-1: 

Paraxonase-1

PPAR: 

Peroxisome proliferation-activated receptor

QUICKI: 

Quantitative Insulin Sensitivity Check Index

ROS: 

Reactive oxygen species

Sirt-1: 

Sirtuin-1

SOD: 

Superoxide dismutase

TC: 

Total cholesterol

TG: 

Triglyceride

TMRC: 

Traditional Medicine Research Center

TNF-α: 

Tumor necrosis factor-alpha

TPN: 

Total parenteral nutrition

Declarations

Acknowledgements

This PhD thesis was supported by the Tehran University of Medical Sciences. The cooperation of the NIOC Central Hospital in Tehran is acknowledged.

Funding

Funding of the trial is supported by the Tehran University of Medical Sciences.

Availability of data and materials

Not applicable.

Authors’ contributions

MDM, GS, and SAK conceived and developed the idea for the paper and revised the manuscript. SM, SMA, MBF and SAJT contributed to data collection. MBF wrote numerous drafts. MQ contributed to statistical interpretations. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

This trial is being conducted with the approval of the Ethics Committee of the Tehran University of Medical Sciences (Ethical Code: IR.TUMS.REC.1394.791). An Informed Consent Form (in Persian) is being obtained from all the participants. Participation is free, and a patient can withdraw at whatever point the person feels they are unable to continue. In this study, lifestyle advice will be presented free to the participants and there is no bar to receiving the other health care services of the center. Side effects of the supplements have not been reported in previous studies. The personal information of participants will be kept secret before, during, and after the trial.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences
(2)
Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences
(3)
National Iranian Oil Company (NIOC) Central Hospital
(4)
Non-Communicable Diseases Research Center, Alborz University of Medical Sciences
(5)
Baqiyatallah Research Center for Gastroenterology and Liver Diseases (BRCGL), Baqiyatallah University of Medical Sciences

References

  1. Sherlock S, Dooley J. Diseases of the liver and biliary system. 11th ed. Oxford: Blackwell Science; 2002. p. 423.Google Scholar
  2. Adibi A, Jaberzadeh-Ansari M, Dalili AR, Omidifar N, Sadeghi M. Association between nonalcoholic fatty liver disease (NAFLD) and coronary artery disease (CAD) in patients with angina pectoris. Open J Med Imaging. 2013;3:97–101. doi:10.4236/ojmi.2013.33015.View ArticleGoogle Scholar
  3. Amirkalali B, Poustchi H, Keyvani H, Khansari MR, Ajdarkosh H, Maadi M, Sohrabi MR, Zamani F. Prevalence of non-alcoholic fatty liver disease and its predictors in north of Iran. Iran J Public Health. 2014;43(9):1275–83.PubMedPubMed CentralGoogle Scholar
  4. Bagheri Lankarani K, Ghaffarpasand F, Mahmoodi M, Lotfi M, Zamiri N, Heydari ST, Fallahzadeh MK, Maharlouei N, Babaeinejad M, Mehravar S, Geramizadeh B. Non alcoholic fatty liver disease in Southern Iran: a population based study. Hepat Mon. 2013;13(5):e9248.View ArticleGoogle Scholar
  5. Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic and clinical implications. Hepatology. 2010;51(2):679–89. doi:10.1002/hep.23280.View ArticlePubMedPubMed CentralGoogle Scholar
  6. Sahebkar A. Potential efficacy of ginger as a natural supplement for nonalcoholic fatty liver disease. World J Gastroenterol. 2011;17(2):271–2. doi:10.3748/wjg.v17.i2.271.View ArticlePubMedPubMed CentralGoogle Scholar
  7. McCullough A. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis. 8(3):521–33. doi:10.1016/j.cld.2004.04.004.
  8. Musso G, Molinaro F, Paschetta E, Gambino R, Cassader M. Lipid modifiers and NASH: statins, ezetimibe, fibrates, and other agents. In; McCullough AJ, Day CP, editors. Non-alcoholic fatty liver disease. Wiley Blackwell; 2013. p. 293–307. http://onlinelibrary.wiley.com/doi/10.1002/9781118556153.ch26/pdf.
  9. Gaharwar R, Trikha S, Margekar SL, Jatav OP, Ganga PD. Study of clinical profile of patients of non alcoholic fatty liver disease and its association with metabolic syndrome. J Assoc Physicians India. 2015;63(1):12–6.PubMedGoogle Scholar
  10. National Guideline Centre (UK). Non-alcoholic fatty liver disease: assessment and management. London: (NICE Guideline, No. 49.) 5, Risk factors for NAFLD; 2016. Available from: https://www.ncbi.nlm.nih.gov/books/NBK384735/.
  11. Lau E, Carvalho D, Freitas P. Gut microbiota: association with NAFLD and metabolic disturbances. Biomed Res Int. 2015; Article ID 979515. 9 pages. doi:10.1155/2015/979515.
  12. Camps J, Marsillach J, Rull A, Alonso-Villaverde C, Joven J. Interrelationships between paraoxonase-1 and monocyte chemoattractant protein-1 in the regulation of hepatic inflammation. Adv Exp Med Biol. 2010;660:5–18. doi:10.1007/978-1-60761-350-3_2.View ArticlePubMedGoogle Scholar
  13. Atamer A, Bilici A, Yenice N, Selek S, Ilhan N, Atamer Y. The importance of paraoxonase 1 activity, nitric oxide and lipid peroxidation in hepatosteatosis. J Int Med Res. 2008;36:771–6.View ArticlePubMedGoogle Scholar
  14. Khateeb J, Gantman A, Kreitenberg AJ, Aviram M, Fuhrman B. Paraoxonase 1 (PON1) expression in hepatocytes is upregulated by pomegranate polyphenols: a role for PPAR-gamma pathway. Atherosclerosis. 2010;208(1):119–25. doi:10.1016/j.atherosclerosis.2009.08.051.View ArticlePubMedGoogle Scholar
  15. Yoon JH, Baek SJ. Molecular targets of dietary polyphenols with anti-inflammatory properties. Yonsei Med J. 2005;46(5):585–96. doi:10.3349/ymj.2005.46.5.585.View ArticlePubMedPubMed CentralGoogle Scholar
  16. Santangelo C, Varì R, Scazzocchio B, Benedetto RD, Filesi C, Masella R. Polyphenols, intracellular signalling and inflammation. Ann Ist Super Sanita. 2007;43(4):394–405.PubMedGoogle Scholar
  17. Penumetcha M and Santanam. Nutraceuticals as ligands of PPARγ. PPAR Research. 2012:1–7. Article ID 858352. doi:10.1155/2012/858352.
  18. Park MJ, Kim DI, Choi JH, Heo YR, Park SH. New role of irisin in hepatocytes: the protective effect of hepatic steatosis in vitro. Cell Signal. 2015. doi:10.1016/j.cellsig.2015.04.010.Google Scholar
  19. Gamas L, Matafome P, Seiça R. Irisin and myonectin regulation in the insulin resistant muscle: implications to adipose tissue: muscle crosstalk. J Diabetes Res. 2015:8. Article ID 359159. doi:10.1155/2015/359159.
  20. Panati K, Suneetha Y, Narala VR. Irisin/FNDC5—An updated review. Eur Rev Med Pharmacol Sci. 2016;20:689–97.PubMedGoogle Scholar
  21. Sanchis-Gomar F, Perez-Quilis C. The p38–PGC-1α–irisin–betatrophin axis. Adipocyte. 2014;3(1):67–8. doi:10.4161/adip.27370.View ArticlePubMedGoogle Scholar
  22. Arias-Loste MT, Ranchal I, Romero-Gómez M, Crespo J. Irisin, a link among fatty liver disease, physical inactivity and insulin resistance. Int J Mol Sci. 2014;15:23163–78. doi:10.3390/ijms151223163.View ArticlePubMedPubMed CentralGoogle Scholar
  23. Chen JQ, Huang YY, Gusdon AM, Qu S. Irisin: a new molecular marker and target in metabolic disorder. Lipids Health Dis. 2015;14(1):2–6.View ArticlePubMedPubMed CentralGoogle Scholar
  24. Saleh BO, Majeed MJ, Oreaby GM. Irisin peptide is myokine, anti-obesity and anti-lipidemic factor. Am J Res Comput. 2015;3(1):20–30.Google Scholar
  25. Bluher S, Panagiotou G, Petroff D, Markert J, Wagner A, Klemm T, et al. Effects of a 1-year exercise and lifestyle intervention on irisin, adipokines, and inflammatory markers in obese children. Obesity. 2014. doi:10.1002/oby.20739.Google Scholar
  26. Zhang HJ, Zhang XF, Ma ZM, Pan LL, Chen Z, Han HW, et al. Irisin is inversely associated with intrahepatic triglyceride contents in obese adults. J Hepatol. 2013;59:557–62.View ArticlePubMedGoogle Scholar
  27. Salminena A, Kaarniranta K, Kauppinenc A. Crosstalk between oxidative stress and SIRT1: impact on the aging process. Int J Mol Sci. 2013;14:3834–59. doi:10.3390/ijms14023834.View ArticleGoogle Scholar
  28. Elliott PJ, Jirousek M. Sirtuins: novel targets for metabolic disease. Curr Opin Investig Drugs. 2008;9(4):371–8.PubMedGoogle Scholar
  29. Chung S, Yao H, Caito S, Hwang J, Arunachalam G, Rahman I. Regulation of SIRT1 in cellular functions: role of polyphenols. Arch Biochem Biophys. 2010;501:79–90. doi:10.1016/j.abb.2010.05.003.View ArticlePubMedPubMed CentralGoogle Scholar
  30. Farris PK. Innovative cosmeceuticals: sirtuin activators and anti-glycation compounds. Semin Cutan Med Surg. 2011;30:163–6. doi:10.1016/j.sder.2011.05.004.View ArticlePubMedGoogle Scholar
  31. Salminena A, Kauppinenc A, Kaarniranta K. Phytochemicals suppress nuclear factor-kB signaling: impact on health span and the aging process. Curr Opin Clin Nutr Metab Care. 2012;15(1):23–8. doi:10.1097/MCO.0b013e32834d3ae7.View ArticleGoogle Scholar
  32. Han X, Shen T, Lou H. Dietary polyphenols and their biological significance. Int J Mol Sci. 2007;8:950–88. PMCID: PMC3871896.View ArticlePubMed CentralGoogle Scholar
  33. Brglez Mojzer E, Knez Hrnčič M, Škerget M, Knez Ž, Bren U. Polyphenols: extraction methods, antioxidative action, bioavailability and anticarcinogenic effects. Molecules. 2016;21(7):901.View ArticleGoogle Scholar
  34. Kim JA, Kim DK, Kang OH, Choi YA, Park HJ, Choi SC, Kim TH, Yun KJ, Nah YH, Lee YM. Inhibitory effect of luteolin on TNF-α-induced IL-8 production in human colon epithelial cells. Int Immunopharmacol. 2005;5(1):209–17. doi:10.1016/j.intimp.2004.09.027.View ArticlePubMedGoogle Scholar
  35. Hämäläinen M, Nieminen R, Vuorela P, Heinonen M, Moilanen E. Anti-inflammatory effects of flavonoids: genistein, kaempferol, quercetin, and daidzein inhibit STAT-1 and NF-kappaB activations, whereas flavone, isorhamnetin, naringeninand pelargonidin inhibit only NF-kappaBactivation along with their inhibitory effect on iNOS expression and NO production in activated macrophages. Mediators Inflamm. 2007;2007:Article ID 45673. doi:10.1155/2007/45673. 10 pages.View ArticleGoogle Scholar
  36. Kim HK, Park HR, Lee JS, Chung TS, Chung HY, Chung J. Down-regulation of iNOS and TNF-alpha expression by kaempferol via NF-kappaB inactivation in aged rats gingival tissues. Biogerontology. 2007;8(4):399–408.View ArticlePubMedGoogle Scholar
  37. Davis JM, Murphy EA, Martin DC. Effects of the dietary flavonoid quercetin upon performance and health. Curr Sports Med Rep. 2009;8(4):206–13. doi:10.1249/JSR.0b013e3181ae8959.View ArticlePubMedGoogle Scholar
  38. Da-Silva WS, Harney JW, Kim BW, Li J, Bianco SD, Crescenzi A, Christoffolete MA, Huang SA, Bianco AC. The small polyphenolic molecule kaempferol increases cellular energy expenditure and thyroid hormone activation. Diabetes. 2007;56(3):767–76.View ArticlePubMedGoogle Scholar
  39. Dixon JB, Bhathal PS, Hughes NR, O’Brien PE. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology. 2004;39:1647–54.View ArticlePubMedGoogle Scholar
  40. Luyckx FH, Desaive C, Thiry A, Dewe W, Scheen AJ, Gielen JE, Lefebvre PJ. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord. 1998;22:222–6.View ArticlePubMedGoogle Scholar
  41. Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology. 1990;99:1408–13.View ArticlePubMedGoogle Scholar
  42. Ueno T, Sugawara H, Sujaku K, Hashimoto O, Tsuji R, Tamaki S, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol. 1997;27:103–7.View ArticlePubMedGoogle Scholar
  43. Shah K, Stufflebam A, Hilton TN, Sinacore DR, Klein S, Villareal DT. Diet and exercise interventions reduce intrahepatic fat content and improve insulin sensitivity in obese older adults. Obesity. 2009;17:2162–8.View ArticlePubMedPubMed CentralGoogle Scholar
  44. Katan MB. Weight-loss diets for the prevention and treatment of obesity. N Engl J Med. 2009;360:923–5.View ArticlePubMedGoogle Scholar
  45. Zelber-Sagi S, Ratziu V, Oren R. Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence. World J Gastroenterol. 2011;17(29):3377–89. doi:10.3748/wjg.v17.i29.3377.View ArticlePubMedPubMed CentralGoogle Scholar
  46. Verma SK, Jain V, Katewa SS. Blood pressure lowering, fibrinolysis enhancing and antioxidant activities of cardamom (Elettaria cardamomum). Indian J Biochem Biophys. 2009;46:503–6.PubMedGoogle Scholar
  47. Vijayan KK, Madhusoodanan KJ, Radhakrishnan VV, Ravindran PN. Properties and end-uses of cardamom. In Cardamom. The genus Elettaria. Ravindran PN, Madhusoodanan KJ (eds.). London: Taylor & Francis; 2002;269–283. https://books.google.com/books?hl=en&lr=&id=tnH1bFGKuRoC&oi=fnd&pg=PA269&dq=properties+and+end-uses+of+cardamom,+cardamom+the+genus+Elettaria.&ots=LXqh6C-OhR&sig=xAHCqPcaI_FX_cxWqxpK3o60k14#v=onepage&q=properties%20and%20end-uses%20of%20cardamom%2C%20cardamom%20the%20genus%20Elettaria.&f=false.
  48. Suneetha WJ, Krishnakantha TP. Cardamom extract as inhibitor of human platelet aggregation. Phytother Res. 2005;19:437–40. doi:10.1002/ptr.1681.View ArticlePubMedGoogle Scholar
  49. Aggarwal BB, Kunnumakkara AB. Molecular Targets and Therapeutic Uses of Spices - Modern Uses for Ancient Medicine. 430 p [Different chapters written by experts compiling therapeutic uses of spices of selected spices, fenugreek in the present case]. Singapore: World Scientific Publishing Co. Pvt. Ltd. pp. 65–85. https://books.google.com/books?id=xblX4RL_qQgC&q=65#v=snippet&q=65&f=false.
  50. Ekhlasi G, Shidfar F, Agah S, Merat S, Hosseini KAF. Effect of pomegranate juice intake on lipid profile in patients with nonalcoholic fatty liver disease. Razi J Med Sci. 2013;20(111):30–9 [in Farsi].Google Scholar
  51. Musso G, Gambino R, Cassader M, Pagano G. A Meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology. 2010;52:79–104.View ArticlePubMedGoogle Scholar
  52. Verma SK, Jain V, Singh DP. Effect of greater cardamom (Amomum subulatum Roxb.) on blood lipids, fibrinolysis and total antioxidant status in patients with ischemic heart disease. Asian Pacific J Trop Dis. 2012;2:S739–43.View ArticleGoogle Scholar
  53. Natural Medicine Comprehensive Database (NMCD). http://www.naturaldatabase.com. Accessed 21 Aug 2012.
  54. The lab tests online. Laboratory methods used for medical lab testing (enzyme-linked immunosorbent assay (ELISA)) [Internet]. 2012. [cited 26 Feb 2017]. Available from: https://labtestsonline.org/understanding/features/methods/start/2/. Accessed 26 Feb 2017.
  55. Jazayeri S, Nouri M, Pour-Ebrahim R, Fakhrzadeh H, Larijani B. Food and nutrient intake status in urban population (20–60 years) of population research center of Tehran University of Medical Sciences. Iran J Diab Lipid. 2005;1(3):81–9 [in Farsi].Google Scholar
  56. Qaffarpour M, Houshyar-Rad A, Kianfar H. Guides of home scales, conversion coefficients and percentage of Iranian foods. Tehran: Agricultural Sciences Publication; 2000 [in Farsi].Google Scholar
  57. The IPAQ group. International Physical Activity Questionnaire [Internet]. 2017. [cited 26 Feb 2017]. Available from: https://sites.google.com/site/theipaq/.
  58. Booth ML, Ainsworth BE, Pratt MI, Ekelund U, Yngve AG, Sallis JF, Oja PE. International Physical Activity Questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003;195(9131/03):3508–1381.Google Scholar
  59. Dinger M, Behrens T, Han J. Validity and Reliability of the International Physical Activity Questionnaire in College Students. Am J Health Educ. 2006;37(6):337–43.View ArticleGoogle Scholar
  60. Lee PH, Macfarlane DJ, Lam TH, Stewart SM. Validity of the International Physical Activity Questionnaire short form (IPAQ-SF): a systematic review. Int J Behav Nutr Phys Act. 2011;8:115.View ArticlePubMedPubMed CentralGoogle Scholar
  61. Vafai-Najar A, Vahedian-Shahroodi M, Tehrani H, Dogonchi M, Lael-Monfared E. The effectiveness of physical activity training on depersonalization of employees. Iran J Health Educ Health Promot. 2015;3(2):116–24.Google Scholar
  62. Baghiani-Moghaddam MH, Bakhtari-Aghdam F, Asghari-Jafarabadi M, Allahverdipour H, Saeed Dabagh-Nikookheslat S, Nourizadeh R. Comparing the results of pedometer-based data and International Physical Activity Questionnaire (IPAQ). J Health Syst Res. 2013;9(6):605–12.Google Scholar

Copyright

© The Author(s). 2017